Daily Stock Analysis, ALXN, Alexion Pharmaceuticals Inc, priceseries

Alexion Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
132.00
Close
130.09
High
133.89
Low
127.70
Previous Close
132.37
Daily Price Gain
-2.28
YTD High
141.86
YTD High Date
Apr 10, 2019
YTD Low
95.16
YTD Low Date
Jan 2, 2019
YTD Price Change
32.04
YTD Gain
32.68%
52 Week High
141.86
52 Week High Date
Apr 10, 2019
52 Week Low
92.56
52 Week Low Date
Dec 24, 2018
52 Week Price Change
24.05
52 Week Gain
22.68%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 4. 2017
127.11
Jan 17. 2017
135.89
8 Trading Days
6.91%
Link
LONG
Apr 24. 2017
119.54
May 8. 2017
126.12
10 Trading Days
5.50%
Link
LONG
Jun 9. 2017
105.38
Jun 30. 2017
121.80
15 Trading Days
15.58%
Link
LONG
Jul 18. 2017
126.77
Aug 10. 2017
134.23
17 Trading Days
5.89%
Link
LONG
Jun 29. 2018
124.15
Jul 26. 2018
132.69
18 Trading Days
6.88%
Link
LONG
Sep 18. 2018
120.82
Oct 5. 2018
131.82
13 Trading Days
9.11%
Link
LONG
Jan 4. 2019
106.00
Feb 6. 2019
121.30
22 Trading Days
14.44%
Link
LONG
Feb 12. 2019
124.26
Mar 6. 2019
131.97
15 Trading Days
6.20%
Link
Company Information
Stock Symbol
ALXN
Exchange
NasdaqGS
Company URL
http://www.alexion.com
Company Phone
2032722596
CEO
Ludwig N. Hantson
Headquarters
Connecticut
Business Address
100 COLLEGE STREET, NEW HAVEN, CT 06510
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000899866
About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in New Haven, CT.

Description

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.